Описание
Concurrent use of colchicine and pravastatin carries a small theoretical risk of myopathy, as both drugs individually can cause muscle toxicity, though the combination is better tolerated than colchicine with CYP3A4-metabolised statins.
Механизм
Colchicine inhibits microtubule polymerisation in muscle cells; pravastatin inhibits cholesterol synthesis required for membrane integrity; the combination may have additive myotoxic effects through complementary mechanisms.
Клиническое значение
Case reports of myopathy with colchicine-statin combinations exist; pravastatin is considered lower risk than lipophilic statins because it is not a CYP3A4 substrate.
Тактика ведения
Monitor for unexplained muscle pain, tenderness, or weakness; measure CK if symptoms occur; the combination is generally acceptable with appropriate vigilance.
Медицинский отказ от ответственности
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.